U.S. FDA's list of HPHCs

      Comparison between HPHC levels in THS 2.2 aerosol and cigarette smoke

      17 March 2023

      In 2012, the U.S. Food and Drug Administration (FDA) published a list of harmful and potentially harmful constituents (HPHCs) found in tobacco products and tobacco smoke, known as the FDA 93 list as it comprises 93 compounds or classes of compounds. This list covers toxicants linked to diseases such as cancer and cardiovascular disease, among others. 

      Also in 2012, the FDA published a guidance document for the tobacco industry for the reporting of HPHCs in tobacco smoke, which included 18 analytes to serve as a representative sample from among the FDA 93 list. These 18 analytes focus on smoke constituents for which testing and analytic methods are well established and widely available, and it included representatives of several different chemical classes. In our PMI-58 list of analytes, we include all 18 of those analytes in addition to recommended analytes from lists published by the World Health Organization and Health Canada.  

      Below, we’ve listed the levels of those HPHCs (with the exception of nicotine) measured in the smoke of a standard reference cigarette (3R4F) and the aerosols of two versions of our Tobacco Heating System (THS 2.2), the THS 2.2 Regular and the THS 2.2 Smooth Menthol. In all cases where a comparison could be made, we found that HPHC levels in the THS were lower compared to 3R4F, with an average reduction of more than 90.5% on a stick basis for THS 2.2 Regular and more than 91.0% on a stick basis for THS 2.2 Smooth Menthol.

      The reductions in this table are fully in line with the one previously calculated using the PMI-58 list. The similarity of the results between the THS regular and THS menthol also show that the reduction in levels of HPHCs is related to the heat-not-burn principle and not impacted by the nature of the flavor system.

      Here are the levels of HPHCs, as well as standard deviation (SD), for the THS 2.2 Regular and THS 2.2 Smooth Menthol, compared to 3R4F. The number of replicates for each analyte is 3. All analyses were conducted by Labstat International ULC (Kitchener, ON, Canada), an independent laboratory, according to their own methods and protocols. The standard Health Canada Intense smoking regime was applied to both the 3R4F and the THS.

      Abbreviations:

      • AαC: 2-Amino-9H-pyrido[2,3-b]indole
      • CDD: Chlorodibenzo-p-dioxin
      • CDF: Chlorodibenzofuran
      • CO: Carbon monoxide
      • Glu-P-1: 2-Amino-6-methyldipyrido[1,2-a: 3',2'-d]imidazole
      • Glu-P-2: 2-Aminodipyrido[1,2-a: 3',2'-d]imidazole
      • IQ: 2-Amino-3-methylimidazo[4,5-f]quinoline
      • MeAαC: 2-Amino-3-methyl)-9H-pyrido[2,3-b]indole
      • NDEA: N-Nitrosodiethylamine
      • NDELA : N-Nitrosodiethanolamine
      • NDMA: N-Nitrosodimethylamine
      • NEMA: N-Nitrosomethylethylamine
      • NMOR: N-Nitrosomorpholine
      • NPIP: N-Nitrosopiperidine
      • NPYR: N-Nitrosopyrrolidine
      • PAHs: Polycyclic aromatic hydrocarbons
      • PhIP: 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine
      • Trp-P-1: 3-Amino-1,4-dimethyl-5H-pyrido[4,3-b]indole
      • Trp-P-2: 1-Methyl-3-amino-5H-pyrido[4,3-b]indole
      • TSNA: Tobacco-specific nitrosamines
      Related Articles
      PMI's aerosol chemistry list of 58 constituents
      We regularly monitor the levels of harmful chemicals. See which chemicals are part of the PMI 58 list.
      PMI Presents to US FDA Advisory Committee
      The presentation covers: THS heating technology, assessment results, perception & behavior data, plans to introduce THS in the U.S., and population health impact modeling.
      A group of people working together, surrounded by papers and laptop.
      U.S. FDA Premarket tobacco products application
      The assessment of the product submitted as a Premarket Tobacco Product Application to U.S. FDA.
      Moira Gilchrist
      Why the US FDA authorized THS to be marketed in US
      Dr. Moira Gilchrist discusses several of the key reasons behind the U.S. FDA's decision to authorize the sale of the heated tobacco product.
      Scientists walking across bridges in the Cube
      U.S. FDA Modified Risk Tobacco Product (MRTP) Application
      The assessment of IQOS is described in our Modified Risk Tobacco Product (MRTP) applications to U.S. FDA.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.